How to Verify a Peptide Lot in 90 Seconds

You have a vial in your hand. The label says BPC-157, 10 mg, with a lot number printed under the barcode. Before you reconstitute, weigh, or pipette anything into a flask, you have one job: confirm that the material in front of you matches the certificate of analysis the vendor claims to have on file.

This is the single most important quality check a research peptide buyer can do, and almost nobody does it. The reason is friction. Most vendors either do not publish per-lot data at all, or they bury a generic “specification sheet” three menus deep on their site. By the time you find it, you have already moved on.

A well-designed vendor verification system eliminates that friction. You type the lot number from the bottle, you get the actual CoA PDF for that specific lot — generated by an independent analytical laboratory at the time of release, not a template recycled across batches. The whole loop should take about 90 seconds. This post walks through the protocol step by step so you can run it standing at your bench.

Why per-lot verification matters

Research peptides are not commodities. Two batches of the same compound, synthesized in the same facility on the same SPPS resin, can come off the line with measurably different impurity profiles. Coupling efficiency drifts. Deletion sequences accumulate. Trifluoroacetate counterion content varies with the HPLC purification gradient. The only way to know what is actually in the vial in front of you is to read a CoA tied to that specific lot — not a generic spec sheet for the compound class.

This is the framework that USP General Chapter <621> formalizes for chromatographic identity and purity testing, and that ICH Q2(R2) requires for analytical method validation in any regulated environment. Researchers buying for in vitro and animal-study work are not formally bound by either standard, but the underlying logic is the same: the certificate has to describe the actual material, not a marketing target.

built /verify/ because per-lot transparency is the cheapest and most defensible trust signal a vendor can offer. If the CoA is real, publishing it costs nothing. If it is not real, no amount of brand copy will paper over what an HPLC trace shows.

The 90-second protocol

Run this every time a shipment arrives. Before reconstitution.

Find the lot number on the vial label. It will be printed on the side label, typically formatted as a date prefix plus a sequence (for example, L240615-04). Placement varies by vendor — typically under the compound name or below the barcode. If the vial is in a tamper-evident pouch, the lot is also printed on the outer pouch — they should match.
Go to the vendor’s verification portal. No login should be required. The page is typically a single input field.
Enter the lot number exactly as printed. Case and dashes matter. Copy-paste from the pouch barcode if you have a reader handy.
The system returns the actual CoA PDF for that specific lot. Not a generic compound spec. Not a template. A PDF generated by the analytical lab on the date the lot was released, with the lot number printed in the document header.
Verify the CoA against the bottle. Use the checklist in the next section. If anything does not match, stop and contact us before using the material.

That is the entire loop. From vial in hand to verified CoA on screen, 90 seconds is a generous estimate.

What to check on the returned CoA

Open the PDF and walk through this table before you log the receipt in your inventory system.

The two-instrument pair — reversed-phase HPLC for purity, mass spectrometry for identity — is the accepted standard for synthetic peptide characterization. Either one alone is insufficient. HPLC tells you how clean the main peak is but not what the main peak actually is. MS confirms identity but does not quantify impurities. You need both.

One detail that catches new buyers: net peptide content is not the same as HPLC purity. A vial labeled “10 mg” of a 99 percent pure peptide may contain only 8 mg of actual peptide once the TFA counterion, residual water, and salt are accounted for. The CoA should report net peptide content (typically by nitrogen analysis or amino acid analysis) as a separate line item. This is the number you use for molarity calculations, not the gross mass on the label. The deeper guide to reading a peptide CoA walks through this distinction in more detail.

Red flags — what not to accept

If any of the following are true when you run the protocol, do not use the material. Contact the vendor and request a replacement or a refund.

The CoA shows a different lot number than the bottle. This is the single most common failure mode in the industry. It usually means the vendor is reusing a template CoA from a prior batch.
HPLC purity is reported below 99.0 percent. Research-grade peptides should clear this bar. Anything lower belongs in a different product tier.
Mass spec is missing, or the observed mass does not match the theoretical mass within plus or minus 0.5 Da. A 1 Da gap typically indicates a deamidation product. Larger gaps indicate deletion sequences or wrong compound entirely.
No analyst signature. Unsigned PDFs are draft documents and have no release authority.
The same CoA appears for multiple lots. Run the protocol on two different bottles of the same compound with different lot numbers. If the same PDF comes back for both, the vendor is not actually performing per-lot analysis.
The “third-party lab” is a subsidiary of the vendor or the synthesis house. This is testing, but it is not independent testing. A genuine third party has no commercial interest in the result.

Why most vendors do not publish per-lot CoAs

The honest answer is cost. Independent third-party analysis runs roughly 200 to 400 USD per lot for the HPLC plus MS pair, and the synthesis house typically provides a “spec sheet” for free. Most research peptide vendors take the free spec sheet, brand it with their own logo, and call it a CoA. The document is technically accurate for the synthesis run but it is not lot-specific, not independent, and not aligned with the USP <1086> framework for impurity profiling.

A smaller subset of vendors run their own in-house HPLC and call that verification. In-house testing is better than nothing — it at least confirms the vendor opened a vial — but it is structurally the same conflict of interest as a restaurant grading its own kitchen.

Per-lot independent verification is the standard a serious research buyer should require. It is also the standard that protects the vendor: if a buyer ever disputes purity, the independent CoA is the document that settles the question.

Verification infrastructure

A quality vendor sends every lot to an independent analytical laboratory for HPLC purity, mass spec identity confirmation, and net peptide content determination. The lab generates a signed CoA tied to the specific lot number, and that PDF is what a verification portal should return when you enter the lot.

We do not name the lab publicly on the marketing site because the lab prefers it that way — they work with multiple vendors and would rather not field inbound queries — but the lab name, address, and accreditation are printed in the CoA footer. You see it the moment the verification loop completes.

A well-designed verification portal accepts any historical lot number printed on a published CoA — the system should not require you to be a customer to load a PDF. If you want to test a vendor’s system before ordering, pick a recent lot number from a product page and try loading its CoA.

Closing — make the 90 seconds a habit

The protocol works because it is short enough to do every time. Verification that takes ten minutes gets skipped on a busy day. Verification that takes 90 seconds becomes part of receiving a shipment, like checking the cold-chain indicator or the desiccant packet.

For a deeper walkthrough of the CoA document itself — how to read the chromatogram, interpret the mass spec, and spot doctored PDFs — see the companion post on how to read a peptide CoA. For the verification tool itself, /verify/ is one click from the homepage and bookmarked on the bench browser of every staff member.

Selected references

United States Pharmacopeia. General Chapter <621> Chromatography. USP-NF. Defines system suitability, retention time, and integration standards for HPLC methods used in identity and purity testing.
United States Pharmacopeia. General Chapter <1086> Impurities in Drug Substances and Drug Products. USP-NF. Framework for impurity profiling and reporting thresholds applicable to synthetic peptide characterization.
International Council for Harmonisation. ICH Q2(R2) Validation of Analytical Procedures. 2023. Specifies validation parameters (specificity, accuracy, precision, linearity) required for analytical methods supporting identity and purity claims.
International Council for Harmonisation. ICH Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances. Defines what a release specification document — the structural ancestor of a modern CoA — should contain.
D’Hondt, M., Bracke, N., Taevernier, L., et al. “Related impurities in peptide medicines.” Journal of Pharmaceutical and Biomedical Analysis, 2014. Survey of typical impurity classes (deletion sequences, oxidation products, diastereomers) seen in solid-phase peptide synthesis.
Vergote, V., Burvenich, C., Van de Wiele, C., De Spiegeleer, B. “Quality specifications for peptide drugs: a regulatory-pharmaceutical approach.” Journal of Peptide Science, 2009. Discusses net peptide content, counterion accounting, and the HPLC-plus-MS standard for synthetic peptide release testing.

Research Use Only — Disclaimer

All compounds discussed in this article are described for laboratory and research purposes only. They are intended exclusively for in vitro experimentation and use in animal studies under appropriate institutional oversight. They are not drugs, dietary supplements, cosmetics, or food additives. They are not for human consumption and not for any therapeutic, diagnostic, preventive, or palliative purpose.

Nothing in this article constitutes medical advice. No statement should be interpreted as a recommendation that any peptide compound is safe, effective, or appropriate for any use in humans.

Buyers must be at least 21 years of age and must agree to use products strictly for research purposes.